48-hour Induction of Transdermal Buprenorphine to Extended-release Buprenorphine

被引：6

作者：

Azar, Pouya ^{[1
,2
,12
]}

Wong, James S. H. ^{[1
,3
]}

Mathew, Nickie ^{[1
,2
,4
]}

Ignaszewski, Martha J. ^{[1
,5
]}

Partovi, Nilufar ^{[6
,7
]}

Krausz, Reinhard M. ^{[3
]}

Ajidahun, Adedayo ^{[8
]}

Thotakura, Sahithi ^{[9
]}

Harris, Marianne ^{[8
,10
]}

Barrios, Rolando ^{[8
,11
]}

Montaner, Julio S. G. ^{[8
]}

Maharaj, Anil R. ^{[9
]}

机构：

[1] Vancouver Gen Hosp, Integrated Psychiat Pain & Addict Serv, Vancouver, BC, Canada

[2] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada

[3] Univ British Columbia, Dept Psychiat, Addict & Concurrent Disorders Res Grp, Vancouver, BC, Canada

[4] Prov Hlth Serv Author, BC Mental Hlth & Subst Use Serv, Vancouver, BC, Canada

[5] Prov Hlth Serv Author, BC Childrens Hosp, Subst Use Response & Facilitat Serv, Vancouver, BC, Canada

[6] Vancouver Gen Hosp, Pharmaceut Sci, Vancouver, BC, Canada

[7] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada

[8] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada

[9] Univ British Columbia, Fac Pharmaceut Sci, Pharmacokinet Modeling & Simulat Lab, Vancouver, BC, Canada

[10] Univ British Columbia, Fac Med, Dept Family Practice, Vancouver, BC, Canada

[11] Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, Canada

[12] Vancouver Gen Hosp, Integrated Psychiat Pain & Addict Serv, DHCC, Floor 8-2775 Laurel St, Vancouver, BC V5Z 1M9, Canada

来源：

JOURNAL OF ADDICTION MEDICINE | 2024年 / 18卷 / 01期

关键词：

opioid-related disorders; opiate substitution treatment; buprenorphine; fentanyl;

D O I：

10.1097/ADM.0000000000001231

中图分类号：

R194 [卫生标准、卫生检查、医药管理];

学科分类号：

摘要：

Buprenorphine extended-release (BUP-XR) provides sustained delivery of buprenorphine to control withdrawal and craving symptoms in the form of a monthly injectable and has been shown to improve health outcomes in patients with opioid use disorder. It is recommended that patients are stabilized with a transmucosal buprenorphine product, for at least 7 days per the product monograph; however, clinically, this timeline may be expedited. We report a case of a hospitalized patient with unregulated fentanyl use who underwent a successful transdermal buprenorphine induction for 48 hours to initiate BUP-XR with minimal levels of withdrawal and without precipitating opioid withdrawal. The approach described could provide a practical, patient-centered, accelerated induction strategy that, once independently validated, could considerably facilitate the use of BUP-XR.

引用

页码：82 / 85

页数：4

共 21 条

[1] Microinduction of Buprenorphine/Naloxone: A Review of the Literature [J].

Ahmed, Saeed ;

Bhivandkar, Siddhi ;

Lonergan, Brady B. ;

Suzuki, Joji .

AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (04) :305-315

[2]

[Anonymous], 2023, FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

[3]

[Anonymous], 2022, Sublocade (extended-release buprenorphine injection) product monograph

[4] 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method [J].

Azar, Pouya ;

Wong, James S. H. ;

Mathew, Nickie ;

Vogel, Marc ;

Perrone, Jeanmarie ;

Herring, Andrew A. ;

Krausz, Reinhard M. ;

Montaner, Julio S. G. ;

Greenwald, Mark K. ;

Maharaj, Anil R. .

JOURNAL OF ADDICTION MEDICINE, 2023, 17 (02) :233-236

[5] A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder [J].

Azar, Pouya ;

Wong, James S. H. ;

Jassemi, Sara ;

Moore, Eva ;

Vo, Dzung X. ;

Nikoo, Mohammadali ;

Young, Samantha .

AMERICAN JOURNAL ON ADDICTIONS, 2020, 29 (06) :531-535

[6]

British Columbia Centre on Substance Use, 2022, Risk Mitigation in the Context of Dual Public Health Emergencies - Update to Interim Clinical Guidance

[7] Rapid buprenorphine microdosing for opioid use disorder in a hospitalized patient receiving very high doses of full agonist opioids for acute pain management: Titration, implementation barriers, and strategies to overcomes [J].

DeWeese, Jonathan P. ;

Krenz, James R. ;

Wakeman, Sarah E. ;

Peckham, Alyssa M. .

SUBSTANCE ABUSE, 2021, 42 (04) :506-511

[8] A Neuropharmacological Model to Explain Buprenorphine Induction Challenges [J].

Greenwald, Mark K. ;

Herring, Andrew A. ;

Perrone, Jeanmarie ;

Nelson, Lewis S. ;

Azar, Pouya .

ANNALS OF EMERGENCY MEDICINE, 2022, 80 (06) :509-524

[9] Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method [J].

Hammig, Robert ;

Kemter, Antje ;

Strasser, Johannes ;

von Bardeleben, Ulrich ;

Gugger, Barbara ;

Walter, Marc ;

Dursteler, Kenneth M. ;

Vogel, Marc .

SUBSTANCE ABUSE AND REHABILITATION, 2016, 7 :99-105

[10] Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials [J].

Jones, Aksana K. ;

Ngaimisi, Eliford ;

Gopalakrishnan, Mathangi ;

Young, Malcolm A. ;

Laffont, Celine M. .

CLINICAL PHARMACOKINETICS, 2021, 60 (04) :527-540

← 1 2 3 →